市場調査レポート

商品コード

1321834

癌免疫 (IO) 治療薬の世界市場 (2023-2030年)：薬剤タイプ (モノクローナル抗体・チェックポイント阻害剤)・用途 (肺癌・乳癌)・バイオマーカー (PD-L1・BRCA) 別の規模・シェア・成長分析・予測

Global Immuno-Oncology Drugs Market Size, Share, Growth Analysis, By Type of drugs(Monoclonal antibodies, checkpoint inhibitors), By Application(Lung cancer, breast cancer), By Biomarker(PD-L1, BRCA) - Industry Forecast 2023-2030

出版日: 2023年07月16日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 836,870円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 978,980円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,121,090円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の癌免疫 (IO) 治療薬の市場規模は、2021年の603億2,000万米ドル、2022年の705億7,000万米ドルから、予測期間中は17％のCAGRで推移し、2030年には2,478億2,000万米ドルの規模に成長すると予測されています。

生存率の向上、副作用の減少、個別化治療、長期寛解の可能性、新たな治療の選択肢などが、IO治療薬のメリットの一部です。IO治療薬は、癌細胞を正確に標的にする能力があるため、化学療法や放射線療法のような従来の癌治療よりも優れています。また、その集中的な性質により、IO薬は健康な細胞に同じように影響を与えないため、従来の治療法よりも患者への悪影響が少ないものとなっています。

規制当局の承認が世界のIO治療薬市場に有利な成長機会をもたらしています。IO治療薬の市場は、規制当局による承認の結果、大きく拡大しています。医薬品の安全性と有効性は、欧州医薬品庁 (EMA) や米国食品医薬品局 (FDA) のような規制機関によって大きく向上します。医薬品を臨床で使用することを承認する前に、当局は臨床試験の結果を検討し、医薬品の長所と短所を比較検討します。市場成長の重要な要因は、規制当局による新しいIO医薬品の承認です。

バイオマーカーの創出がIO)治療薬市場における重要な動向となっています。新規バイオマーカーの創出は、より正確な患者の選択と治療成績の向上につながるため、IO治療薬市場において重要な研究分野です。

当レポートでは、世界の癌免疫 (IO) 治療薬の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料分析
イノベーションマトリックス
パイプライン製品の分析
マクロ経済指標
主要投資分析
主要成功要因
競合の程度

市場力学と見通し

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制状況
ポーターの分析
将来のディスラプションに関するSkyquestの特別な洞察

世界の癌免疫 (IO) 治療薬市場：薬剤タイプ別

市場概要
モノクローナル抗体
チェックポイント阻害剤
癌ワクチン
サイトカイン
細胞療法
その他

世界の癌免疫 (IO) 治療薬市場：用途別

市場概要
肺癌
乳癌
前立腺癌
黒色腫など

世界の癌免疫 (IO) 治療薬市場：バイオマーカー別

市場概要
PD-L1
BRCA
クラス
EGFR
その他

世界の癌免疫 (IO) 治療薬市場：地域別

市場概要
北米
欧州
アジア太平洋
ラテンアメリカ
中東・アフリカ

競合情勢

トップ5社の比較
主要企業の市場での位置付け
主要企業の採用戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア

主要企業プロファイル

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Biogen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Incyte Corporation
Merck &Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi SA
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Tesaro, Inc.
Xencor, Inc.
Y-mAbs Therapeutics, Inc.

Product Code: SQMIG35I2108

Global Immuno-Oncology Drugs Market size was valued at USD 60.32 billion in 2021 and is poised to grow from USD 70.57 billion in 2022 to USD 247.82 billion by 2030, growing at a CAGR of 17% in the forecast period (2023-2030).

Increased survival rates, decreased side effects, personalized treatment, the possibility of long-term remission, and new therapeutic choices are just a few of the benefits of immuno-oncology drugs. Due to their capacity to target cancer cells precisely, immuno-oncology (IO) medications have a distinct edge over conventional cancer treatments like chemotherapy and radiation therapy. Due to their focused nature, IO medicines have less adverse effects on patients than conventional treatments since they do not affect healthy cells in the same way. Top-down and bottom-up approaches were used to estimate and validate the size of Immuno-Oncology Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The market for immuno-oncology medications is divided into segments based on drug type, application, biomarker, and region. The market is divided into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others based on application. The market is divided into monoclonal antibodies, checkpoint inhibitors, cancer vaccines, cytokines, cell treatments, and others based on the type of drug being used. The market is divided into PD-L1, BRCA, KRAS, EGFR, and other biomarkers. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments

Driver

Regulatory Approvals to Bring Lucrative Growth Opportunities for Players in the Global Immuno-Oncology Drug Market

The market for immuno-oncology (IO) therapies is expanding significantly as a result of regulatory agencies' approval of IO medications. For IO therapies to be marketed and utilized in clinical practice, regulatory approval is necessary, and the approval of new drugs is a good sign for the market for IO drugs. Drug safety and effectiveness are greatly enhanced by regulatory organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Before approving a medicine for use in clinical practice, authorities review the findings of clinical studies and weigh the advantages and disadvantages of the drug. An important factor in the market's growth is the regulatory authorities' approval of new IO medications.

Restraints

High Cost to Hinder Market Growth

The high price of immuno-oncology (IO) medications is one of the factors that can potentially impede the market's expansion. IO medications frequently cost a lot of money, and both patients and medical professionals may find it difficult to afford the cost of therapy. The adoption of IO medications may be constrained by their high price, especially in nations with limited access to affordable healthcare, which could have a detrimental effect on the market's expansion. The high cost of IO medications may also have an impact on how willing insurance providers and public healthcare systems are to pay for medical expenses, which may further restrict patient access to these medications.

Market Trends

The creation of biomarkers is a significant trend in the immuno-oncology (IO) therapeutic market. In order to pinpoint certain patient traits that increase their likelihood of responding to IO medicines, biomarkers are used. By utilizing biomarkers, doctors are better able to determine which patients require IO therapies, as well as to evaluate the effectiveness of the therapy and modify the course of action as necessary. The creation of novel biomarkers is a key area of research in the market for IO drugs since it can result in more accurate patient selection and better treatment outcomes. The creation of biomarkers is a significant trend in the immuno-oncology (IO) therapeutic market. In order to pinpoint certain patient traits that increase their likelihood of responding to IO medicines, biomarkers are used.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Immuno-Oncology Drugs Market by Type of drugs

Market Overview
Monoclonal antibodies
checkpoint inhibitors
cancer vaccines
cytokines
cell therapies
and others

Global Immuno-Oncology Drugs Market by Application

Market Overview
Lung cancer
breast cancer
prostate cancer
melanoma and others

Global Immuno-Oncology Drugs Market by Biomarker

Market Overview
PD-L1
BRCA
KRAS
EGFR
and others

Global Immuno-Oncology Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seattle Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tesaro, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Y-mAbs Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments